Daewoong Pharmaceutical said it will supply its botulinum toxin Nabota to Kuwait, further cementing its presence in the premium aesthetic market across the Middle East.

The company’s latest export marks its fifth market entry in the region and its fourth among the six Gulf Cooperation Council (GCC) countries, following the United Arab Emirates, Saudi Arabia, and Qatar.

The GCC region is widely regarded as a key market for aesthetic and cosmetic medicine due to its high demand and spending power.

“Kuwait, with a per capita income of around $32,000 and a well-developed medical infrastructure, presents significant strategic value,” Daewoong said. “The company plans to use its foothold in Kuwait as a springboard to accelerate Nabota’s rollout across the broader Gulf region.”

Among Korean botulinum toxin brands, Daewoong has the widest market presence in the Middle East. It is actively working to position Nabota as the leading botulinum toxin in the region not only through product exports but also through comprehensive support for local physicians.

Rather than focusing solely on product supply, Daewoong is pursuing a “win-win-win” model that aims to elevate the capabilities of Middle Eastern practitioners, thereby enhancing treatment satisfaction and service quality for patients.

This model is expected to create shared value across the pharmaceutical company, local doctors, and patients.

To this end, Daewoong continues to host academic events including medical conferences, webinars, and training programs covering advanced and proprietary techniques such as its signature combination procedures and “Nabolift.”

The company is also working with local physicians on clinical research initiatives to further validate Nabota’s safety and efficacy.

“Entering Kuwait strengthens Nabota’s position as a premium toxin brand in the Middle East and will help us accelerate our expansion strategy in the region,” Nabota Business Divison Head Yun Jun-soo said. “We will continue to expand our presence across the Gulf by offering differentiated academic activities backed by clinical data and promoting our proprietary techniques.”